UNSPSC 51162010: Aminophylline/potassium iodide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162010 Aminophylline/potassium iodide is a Commodity code that in recent state and local procurement activity encompasses a broader range of pharmaceutical products and pharmacy services than the code name alone suggests. State and local agencies are using this code to solicit naloxone and drug deactivation systems, on-site pharmacy services for employee health plans, generic pharmaceuticals and over-the-counter products through cooperative purchasing, and direct-to-manufacturer prescription programs. The issuing bodies span county health departments, county employee benefit programs, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida (IFB 60459723LAS, response due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, while Hall County, Georgia (RFQ/P #47-010, response due June 4, 2026) requested on-site pharmacy services for approximately 3,005 eligible individuals enrolled in the county's group health insurance plans, including a formulary of 25 medications across multiple therapeutic categories.

Recent activity concentrates in Florida and Georgia, with activity also visible in Minnesota (through MMCAP, a multistate cooperative purchasing vehicle administered by the Minnesota Department of Administration with participation from Oregon and other jurisdictions) and Texas (the Texas Health and Human Services Commission issuing an RFI on direct-to-manufacturer prescriptions in April 2026). The Minnesota Multistate Cooperative Purchasing Alliance RFP (S1070000015802, response due March 26, 2026) sought generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with effective date July 1, 2026. The Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) represents preliminary market research into direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels. Vendors responding across this code should expect requirements for FDA compliance, cGMP certification where applicable, comprehensive insurance coverage including general liability ranging from $2 million to $5 million, drug-supply chain security documentation, and E-Verify compliance for employee eligibility verification.